Cognition Therapeutics Reports 2025 Financial Results and Major Clinical Milestones

Key Highlights

• Strategic Focus on Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis: The company is advancing its lead candidate, zervimesine, towards late-stage clinical development for DLB psychosis, an area with no approved therapies currently.
• Upcoming FDA Meeting: Cognition expects to meet with the FDA Division of Psychiatry by mid-2026 to discuss the registrational pathway for zervimesine in DLB psychosis.
• Alzheimer’s Program Progress: The 545-patient Phase 2 ‘START’ trial in early Alzheimer’s disease has completed enrollment. Topline results are anticipated in 2027, which will determine further advancement in Alzheimer’s indications.
• Financial Strength: As of December 31, 2025, Cognition held \$37.0 million in cash and equivalents, with an additional \$35.7 million in obligated grant funds from the National Institute on Aging. The company estimates its cash runway extends through Q2 2027.
• Reduced Net Loss and Operating Expenses: Net loss for 2025 was \$23.5 million (\$0.32/share), a significant improvement from \$34.0 million (\$0.86/share) in 2024, driven by lower R&D and G&A expenses after completion of key clinical trials.
• Positive Phase 2 Data in DLB: The SHIMMER study in DLB demonstrated strong therapeutic responses across behavioral, cognitive, and movement domains, supporting progression to registrational trials.
• Expanded Access Program for DLB: Launched an expanded access program (NCT06961760) for DLB patients, made possible through philanthropic support.
• Leadership Expansion: Appointment of Dr. David Weinstein as VP of Clinical Development to drive clinical strategy.
• Regulatory Engagement in Alzheimer’s: Completed end-of-Phase 2 meeting with FDA and engaged with the European Medicines Agency (EMA) to align on the Alzheimer’s disease program.
• Increased Shareholder Equity: Total stockholders’ equity doubled to \$34.3 million from \$18.8 million year-over-year.

In-Depth Financial Review

• Research & Development (R&D) Expenses: R&D expenses fell to \$37.2 million in 2025 from \$41.7 million in 2024 as the SHINE and SHIMMER trials concluded. This reduction signals a transition to later-stage development, reducing near-term cash burn.
• General & Administrative (G&A) Expenses: G&A expenses were \$10.6 million in 2025, down from \$12.3 million in 2024, primarily due to lower stock-based compensation.
• Grant Income: Grant income rose to \$23.4 million in 2025, up from \$19.5 million, reflecting continued strong support from the NIH and related foundations.
• Cash and Assets: Cash, cash equivalents, and restricted cash totaled \$37.0 million at year-end 2025, up from \$25.0 million a year before. Total assets increased to \$48.4 million (from \$30.2 million), while total liabilities modestly increased to \$14.1 million.

Clinical and Regulatory Developments

DLB Psychosis Program

• Phase 2 Results: The SHIMMER study (COG1201) provided compelling data, with strong efficacy signals in behavioral and psychosis endpoints, which were presented at the International Lewy Body Dementia Conference.
• Path Forward: Cognition is preparing for a mid-2026 FDA meeting to seek alignment on a registrational trial, aiming to address the unmet need for DLB psychosis therapies.

Alzheimer’s Disease Program

• Phase 2 ‘START’ Trial: Completed enrollment in December 2025 (NCT05531656) for patients with mild cognitive impairment and early Alzheimer’s disease. Topline data expected in 2027 will drive the decision on advancing zervimesine in this area.
• Regulatory Dialogues: The company concluded a successful end-of-Phase 2 meeting with the FDA and engaged the EMA for scientific advice, de-risking future regulatory steps.

Product Pipeline Overview

Zervimesine (CT1812) remains the company’s lead oral, once-daily therapy. It has shown promising safety and efficacy in multiple indications, including DLB, mild-to-moderate Alzheimer’s, and geographic atrophy secondary to dry AMD. The drug is poised for pivotal development in DLB psychosis and potentially in Alzheimer’s, depending on upcoming trial results.

Shareholder Impact and Price-Sensitive Information

• DLB Program Could Be a Major Value Driver: The move to late-stage development for zervimesine in DLB psychosis, with an FDA meeting scheduled, positions the company for potential near-term catalysts that could significantly impact valuation if positive regulatory interactions and trial outcomes follow.
• Alzheimer’s Data as a Mid-Term Catalyst: Completion of the large Phase 2 trial in early Alzheimer’s disease sets up a major data readout in 2027, with the potential to expand the addressable market and attract industry partnerships or acquirers.
• Financial Runway Reduces Dilution Risk: The strengthened cash position and substantial non-dilutive grant funding decrease the likelihood of near-term equity raises, supporting shareholder value.
• Reduced Losses and Increased Equity: Sharply improved net loss and doubled equity highlight prudent cost management and strengthen the investment case.
• Potential for Grant Funding Upside: Ongoing NIH and foundation support could provide additional non-dilutive resources.
• Pipeline Diversification: While zervimesine is the main asset, the company’s platform is applicable to other neurodegenerative disorders, offering long-term optionality.

Conference Call Information

Cognition Therapeutics will host a conference call and webcast at 8:30 a.m. ET to review these results and provide additional clinical and strategic insights. Investors can access the event at the webcast link or via the company’s Investor Relations page. A replay will be available for 90 days.

About Cognition Therapeutics

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, with a strong track record of NIH grant support and a robust, innovative pipeline targeting toxic oligomer-driven pathology in DLB, Alzheimer’s, and other indications.

Disclaimer

This article contains forward-looking statements based on Cognition Therapeutics’ current expectations, plans, and estimates. Actual results may differ materially due to various risks and uncertainties, including those detailed in company filings with the SEC. Investors should not rely solely on forward-looking statements for investment decisions. This does not constitute investment advice.

View COGNITION THERAPEUTICS INC Historical chart here